The present study examined the 5-year longitudinal course of cognitive functioning in a large sample of well-characterized patients with bipolar disorder (BP), compared to healthy controls (HCs), and the influence of cognitive reserve factors (e.g., education and IQ) on cognitive change over time. 
| INTRODUCTION
It has been well established that individuals with bipolar disorder (BP) typically achieve lower neuropsychological test scores compared to healthy controls (HCs) across a number of cognitive domains, including attention, memory, psychomotor speed, and executive functioning.
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However, few studies have examined if and how these cognitive deficits change over time. Past studies have found that older individuals with BP tend to have more functional impairment and neurocognitive impairment and higher rates of dementia. [5] [6] [7] These findings lead to the assumption that individuals with BP may be at increased risk for cognitive decline and therefore suffer a progressive, accelerated neurodegeneration over time. 8, 9 Further, previous cross-sectional work by our group 10 has demonstrated an additive effect of aging and cognitive burden on health-related quality of life, as well as evidence of an age by BP diagnosis interaction in terms of performance on emotion processing, processing speed, and executive functioning tasks.
These findings highlight the importance of studying cognitive changes in aging individuals affected by BP.
Although relatively sparse, a number of recent articles have proposed that progression of cognitive symptoms over time may not differ between individuals diagnosed with BP and HC subjects. [11] [12] [13] In a recent review article examining longitudinal and cross-sectional research on the trajectory of neuropsychological dysfunction among those with BP, Strejilevich and colleagues 13 concluded that evidence does not support progressive neurocognitive decline over time. They noted,
however, that many of the studies to date had methodological limitations such as small sample size and brief neuropsychological batteries.
In other recent work, Gildengers and colleagues 11 explored longitudinal neuropsychological performances in BP over 2 years and found that, although individuals with BP tended to score lower on cognitive measures overall, the change in scores did not differ compared to HCs, suggesting that BP was not related to an accelerated rate of cognitive decline as was previously assumed. Similarly, Santos and colleagues analyzed the longitudinal course of BP cognitive trajectory over a longer time period and again found that BP participants demonstrated a similar cognitive trajectory over time compared to controls, despite performing at lower levels on neuropsychological testing. Again, these findings suggest that having a BP diagnosis was not associated with progressive neurocognitive decline. Further, this work reported that the clinical symptom course of BP (measured by number of mood episodes) was unrelated to cognitive performance over time, indicating that cognitive deficits in BP tend to be stable, following a course similar to that in individuals without a significant psychiatric condition.
Although compelling, data were obtained in a small sample size of 80 BP participants, and further exploration with larger samples and over longer periods of time is needed to better evaluate this hypothesis.
As normative age-related changes can be notable and highly variable studies finding, a null effect of disease by age are likely underpowered with smaller samples over shorter periods of time. Overall, analysis of neurocognitive change in BP is a relatively new area of study, and most work done in the area has been cross-sectional in nature, utilizes small sample sizes over a short follow-up time interval, and has used a brief incomprehensive test battery. were associated with decline. Again, we hypothesized that low CR would be associated with higher rates of decline over the 5-year span. Individuals were excluded from the longitudinal study if they had a history of diagnosed schizophrenia, active substance dependence, or a history of significant neurological disease at the time of study entry.
| METHODS

| Participants
HC participants were excluded from the study if they met diagnostic criteria for a DSM-IV-TR disorder at any time during the 5-year study timeframe, as assessed by biennial clinical interviews (n=11).
Participant data were not used if evidence of substantial intellectual impairment (IQ <70) was present (n=1). Individuals with a history of developmental disorder were also screened out at the initial interview.
Mood states during the neuropsychological assessment were also documented at the time at which they entered the study. At base- 
| Clinical assessment
All participants completed an initial psychodiagnostic interview with an experienced clinician using the Diagnostic Interview for Genetic 
Studies (DIGS 40
)
| Cognitive reserve variables
Proxies for CR in our study included education and premorbid intel- 
| Neuropsychological assessment
| Data analyses
Analyses were completed using the IBM Statistical Package for Social Sciences (Version 21) and Statistical Analysis System. t-tests or chisquare tests were used to determine the significance of demographic differences between the BP and HC groups. Raw scores were converted to Z-scores based on mean HC group scores at baseline and Those who did not demonstrate a decline of >1.5 SD were considered non-decliners (n=104). T-test analyses of the decliners and non-decliners were completed to further assess the significance of differences among groups in terms of CR variables. We used chi-square and t-test analyses to compare the BP decliners and non-decliners on clinical variables including cerebrovascular risk factor/disease variables. Finally, variable regression models were used to determine the relationship between changes in test scores over the 5-year period, as well as the influence of CR variables. As previously noted, CR variables included in our analyses were education and IQ.
| RESULTS
There were no significant differences between the BP and HC groups in terms of education, age, gender, handedness, WASI full-scale IQ or WASI Vocabulary standard score at study entry. Descriptive statistics are presented in Table 1 .
We compared participants who completed 5-year testing (completers; n=283) to those who did not complete it, despite being enrolled in the study for 5 years (non-completers; n=282) to contextualize this sample in terms of attrition. The completers had similar fullscale IQ (P=.27) and education (P=.19) to non-completers but were more likely to be older (mean(SD)=38.97 (13.13) vs mean(SD)=35.90 (14.11); t(237)=−2.68, P=.01) and male (P=.0009).
Next, when differences between groups for neuropsychological test scores at baseline testing and year 5 testing were examined, the BP group showed significantly lower scores on seven of 13 test scores at baseline, and six of 13 test scores analyzed at year 5 as compared to the HC group. Please see Table 2 .
To provide an indicator of overall relative change, change scores were created by calculating the difference in Z-scores for all neuropsychological tests between baseline testing and year 5 testing. See Although not the main analyses, we examined differences in clinical illness variables between decliners and non-decliners among the individuals with BP. See Table S1 . There were no illness features that were significantly different between the decliner and non-decliner groups. Further, there were no differences between the decliners and non-decliners in terms of the presence of cerebrovascular disease or cerebrovascular risk factors. There also was no difference in total medication load when comparing BP decliners to BP non-decliners. When T A B L E 2 (Continued) (Continues) considering the entire sample (HCs and BP patients), the results continued to be non-significant. Age at the time of testing was also included in regression analyses as a covariate, and results indicated that age was related to change on specific measures (see Table 4 ). we did not find evidence for accelerated decline in the 5-year timeframe for BP patients, consistent with an interpretation of additive, but not compounded or accelerated, effects of age and BP. 60 When we identified individuals who demonstrated a significant decline on at least one cognitive measure, we found that decline was significantly associated with lower overall intellectual scores compared to those who did not decline within the BP group only. This finding was not replicated within the HC decliner group. However, we did not find a difference between the BP decliners and BP non-decliners in terms of our CR variables (WASI Vocabulary and education). This finding suggests that overall IQ may be protective for general cognitive decline in BP, but not traditional CR variables as expected.
T A B L E 2 Independent t-test results comparing neuropsychological test scores for bipolar disorder (BP) and healthy control (HC) groups at baseline and year 5 visits
| DISCUSSION
Instead, we found verbal IQ (WASI Vocabulary) and education were related to changes in specific cognitive domains. Specifically, we found that intellectual ability was related to change in performance in terms of visuospatial ability, simple visuomotor attention, and verbal memory in the BP group, three particularly important skills in everyday life. Overall, findings supported our hypotheses and indicate that there does not seem to be evidence of accelerated cognitive decline in BP, and that CR variables were related to change in select areas of cognition. The overall lack of cognitive decline could represent a stable cognitive endophenotype in BP and warrants future exploration. 46, 61 Overall, our sample was highly educated and intelligent, with IQ scores well into the average and high-average ranges, which may account for why we did not find change in more of the cognitive domains assessed. Additionally, a longer period of time, beyond 5 years, may be necessary to detect more significant cognitive change within the groups. Since our cohort was relatively young (mean age =41.6 years), longer studies and analysis of older individuals with BP are warranted.
It is possible that older individuals with BP do experience accelerated cognitive decline and that our sample was too young to allow us to detect this. Our finding that those with a bipolar diagnosis did not experience an increased decline over 5 years is in support of a growing body of new literature, [11] [12] [13] and also contradictory to previous work that has claimed that BP is associated with significant neurocognitive decline. [5] [6] [7] [8] [9] 62 However, our study utilized a large sample of participants with BP and longitudinal methods, which may increase the specificity and generalizability of our findings to BP groups, given the typical high rate of variability between patients. Overall, this finding is important to consider in treatment planning and support for middle-aged and older adults with BP, as these individuals may start at a lower cognitive level, and, with a similar pattern of decline, may reach the point of dementia at an earlier age. Specifically, the BP group tended to have lower baseline neuropsychological scores compared to HCs, and so a 'normal' decline in cognition associated with age may lead to more significant functional deficits as they may reach an objectively more impaired cognitive level, which might also translate into higher levels of occupational disability. While the current study has a number of strengths, there are a few limitations that may reduce the generalizability of our results and should be considered for future studies. In particular, this study utilized participants taking a variety of psychotropic medications and participating in psychosocial treatments for BP and with comorbid conditions, as is common in naturalistic studies of this kind. It is possible that specific medications, such as lithium, had an effect on neurocognitive functioning in our study, but since we did not detect significant T A B L E 3 Independent t-test comparing change scores among bipolar disorder (BP) and healthy control (HC) groups differences between changes in BP and HC groups over time, it is unlikely that medications were related to a significant decline in cognition. Please see Table S1 , which illustrates the total medication load BP participants reported at the time of their initial assessment. Also, the particular neuropsychological test battery utilized in our study was selected for ease of administration and comprehensiveness across cognitive domains known to be affected in BP. 63 Administration time and participant fatigue generally precluded a longer or more comprehensive test battery. Finally, we included BP participants in various mood states in our analyses (euthymic, depressed, and manic), and acute mood symptoms may have influenced overall performance on testing.
However, our preliminary analyses did not find a relationship between decline and mood state, and therefore it seems unlikely that mood at the time of testing significantly influenced our findings. Future work may focus on further characterizing the BP participants who showed evidence of decline over our 5-year timeframe. Use of additional statistical methods (i.e., cluster analyses, etc.) may provide evidence of decliner subtypes, offering more precise ways to identify those in need of future support. Other factors such as substance abuse, history of traumatic brain injury, illness duration, or cardiovascular risk are also important considerations for future research, although these were beyond the scope of our current work.
It is possible that our findings were influenced by test−retest variability in our sample. However, our decision to use a change score cutoff of 1.5 SD below the mean makes it likely that our findings reflect meaningful differences, particularly as we utilized standard neuropsychological measures that are widely accepted in the field and report strong test−retest reliability.
In summary, the present study demonstrated that neurocognitive deficits exist among individuals with BP, though there is generally a high degree of heterogeneity and variability among patients. These deficits seem to be present early in the disorder, but do not progress at a more rapid rate than that experienced by a 'normally' aging healthy adult sample with no psychiatric illness. Further, higher intellectual ability may selectively preserve cognitive abilities over time, particularly for individuals with BP and an above-average IQ. Traditional CR factors (WASI Vocabulary and education) were only partially influential for decline. We would like to emphasize that it is quite difficult to examine CR variables in this population, as the accumulation of CR may be directly impacted by the presentation of disruptive psychological symptoms at a young age.
Our findings provide valuable insight for providers and family members working with patients experiencing BP cognitive symptoms.
Specifically, cognitive training groups or other rehabilitation treatments may be quite beneficial for some BP subgroups, and perhaps less necessary for others. Overall, our findings highlight the importance of intellectual engagement in those with neuropsychiatric illness, which may provide some defense against functional decline with age. This is only a speculation based on a small, but growing, body of literature, however, and significantly more research is needed in this area for continued understanding of the relationship between premorbid intellectual ability, neurocognitive symptoms of BP, and functional decline over time.
